NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.

MLA

Sim, Hao-Wen, et al. “NUTMEG: A Randomized Phase II Study of Nivolumab and Temozolomide versus Temozolomide Alone in Newly Diagnosed Older Patients with Glioblastoma.” Neuro-Oncology Advances, vol. 5, no. 1, Sept. 2023, p. vdad124. EBSCOhost, https://doi.org/10.1093/noajnl/vdad124.

APA

Sim, H.-W., Wachsmuth, L., Barnes, E. H., Yip, S., Koh, E.-S., Hall, M., Jennens, R., Ashley, D. M., Verhaak, R. G., Heimberger, A. B., Rosenthal, M. A., Hovey, E. J., Ellingson, B. M., Tognela, A., Gan, H. K., Wheeler, H., Back, M., McDonald, K. L., Long, A., … Khasraw, M. (2023). NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neuro-Oncology Advances, 5(1), vdad124. https://doi.org/10.1093/noajnl/vdad124

Chicago

Sim, Hao-Wen, Luke Wachsmuth, Elizabeth H Barnes, Sonia Yip, Eng-Siew Koh, Merryn Hall, Ross Jennens, et al. 2023. “NUTMEG: A Randomized Phase II Study of Nivolumab and Temozolomide versus Temozolomide Alone in Newly Diagnosed Older Patients with Glioblastoma.” Neuro-Oncology Advances 5 (1): vdad124. doi:10.1093/noajnl/vdad124.